Search results for "mRNA platform history"

Witness Testimony Keywords from Transcript mRNA platform history, lipid nanoparticle inflammation, spike toxicity claim, pediatric myocarditis risk, risk-benefit in children, plasmid DNA contamination, truncated mRNA Robert Malone MD Physician and mRNA Technology Researcher Expert Witness ID: NCI-W-040 Hearing Toronto One Line Summary mRNA pioneer Dr. Robert Wallace Malone testified regarding his early role in developing mRNA delivery technology in the

Witness Testimony Keywords from Transcript virology expertise, viral evolution theory, mRNA platform Efficacy of the COVID-19 Response in Canada; November 2023 Main Topic Scientific critique of COVID-19 mRNA One Line Summary Virologist presents concerns about mRNA vaccine platform design, regulatory approval virology and molecular genetics, testified regarding concerns about the design and implementation of mRNA He described the technology as a novel gene-based platform utilizing lipid nanoparticles to deliver genetic

Witness Testimony Keywords from Transcript mRNA vaccine regulation, gene therapy definition, EMA exclusion -19 Response in Canada; November 2023 Main Topic Regulatory classification and safety evaluation of mRNA One Line Summary A French pharmacist-biologist argues that mRNA COVID-19 vaccines meet definitions of platforms, which involve injection of synthetic genetic material directing host cells to produce spike She argued that, based on definitions from the FDA and European Medicines Agency (EMA), mRNA vaccines

Witness Testimony Keywords from Transcript pharmacotherapeutic assessment, mRNA manufacturing process marketing authorization, gene therapy classification dispute, batch variability concerns, truncated mRNA Regulatory classification, manufacturing quality control, and safety assessment concerns related to mRNA She explained that although mRNA products meet regulatory definitions of gene therapy due to their nucleic characterized the regulatory review process as insufficiently rigorous given the novelty and complexity of the platform

kinase research, spike protein signaling, lipid nanoparticle delivery, biodistribution variability, mRNA analyzes spike protein signaling effects and raises concerns about off-target molecular consequences of mRNA kinase signaling and cellular regulatory pathways, he described how lipid nanoparticles deliver modified mRNA He testified that biodistribution studies indicate the lipid nanoparticle–mRNA complexes may not remain comprehensive molecular pharmacology and long-term safety testing are typically required for novel biologic platforms

Transcript renin-angiotensin system, ACE2 receptor binding, AT1R overactivation, spike protein effects, mRNA vaccine platform, lipid nanoparticle toxicity, pseudouridine modification, immune dysregulation, vitamin based on spike protein interaction with the renin-angiotensin system and concerns regarding vaccine platform immunological critique of spike-based COVID-19 vaccines, focusing on renin-angiotensin disruption and platform-related Regarding mRNA vaccine technology, Dr.

physician suspension, College investigation, regulatory retaliation claim, excess mortality assertion, mRNA platform critique, immune suppression theory, blood clotting concern, chemotherapy resistance claim, William Makis testified that mRNA vaccines are linked to sudden deaths, aggressive cancers, and immune He asserted that public health authorities ignored early treatment options and that mRNA vaccine technology He expressed concern about ongoing booster campaigns and called for immediate cessation of mRNA vaccine

long-term neurological risk, precautionary principle advocacy, regulatory oversight critique, experimental platform Efficacy of the COVID-19 Response in Canada; November 2023 Main Topic Neuropathological concerns regarding mRNA about spike protein neurotoxicity, biodistribution, and potential long-term neurological effects of mRNA the University of British Columbia, testified regarding potential neurological risks associated with mRNA He stated that novel gene-based platforms should undergo rigorous independent evaluation before widespread

4.7.1 mRNA Vaccines, Public Health, and Safety Concerns 4.7 mRNA Vaccines, Public Health, and Safety However, the rapid adoption of this new platform also introduced a range of safety, regulatory, and public The Vancouver NCI hearings provided a platform for expert witnesses to critically evaluate the risks Concerns About “Shedding” Following vaccination, viral mRNA or mRNA fragments have been shown to occur Recommendations Suspend mRNA Vaccine Roll-out: Implement an immediate moratorium on mRNA vaccines until

Witness Testimony Keywords from Transcript Pfizer documents, mRNA platform, lipid nanoparticles, clinical Flowers further addressed issues related to the mRNA lipid nanoparticle platform, including biodistribution

5.7.1 mRNA Vaccines, Public Health, and Safety Concerns 5.7 Health and Medical Safety 5.7.1 mRNA Vaccines , Public Health, and Safety Concerns Recommendations Suspend mRNA Vaccine Roll-out: Implement an immediate moratorium on mRNA vaccines until independent safety verification is conducted. 2. Support Research and Accountability: Fund long-term studies on the effects of mRNA vaccines.

Witness Testimony Keywords from Transcript mRNA integrity variation, spike protein isoforms, translation One Line Summary A clinical biochemistry professor argues that mRNA vaccine quality variability and spike at the Université du Québec à Trois-Rivières, testified regarding the molecular characteristics of mRNA He explained the mechanism of mRNA vaccination, describing how lipid nanoparticles deliver synthetic He stated that published analyses indicated variability in mRNA integrity, with some batches containing